Rocket Pharmaceuticals, Inc.
NASDAQ:RCKTBiotechnology
+$0.06 today
- Market cap
- $235.60M
- Beta
- 0.47
- P/E (TTM)
- -1.7
- EPS (TTM)
- -$1.87
Volume 2.49M
Average 3.15M
RCKT Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Rocket Pharmaceuticals, Inc.NASDAQ: RCKT
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $17.06M fell 40.0% year over year, behind the -30.1% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 16.2% from the prior quarter. Over 3 fiscal years it compounded at +13.7% a year.
Context
- Selling, general & admin increased in 2 of the last 3 fiscal years.
What to watch
Whether selling, general & admin reaches the consensus estimate from 8 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -15.2% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $17.06M+16.2% QoQ
- Last fiscal yearDec 2025
- $86.5M-15.2% YoY
- LTMMar 2026
- $75.11M-30.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -40.0% | -100.0% | -60.0 pp |
| 1 year | -15.2% | -100.0% | -84.8 pp |
| 3-year CAGR | +13.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 86.5M USD
- Year-over-year change
- -15.2%
- 4-year CAGR
- +20.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 86.5M | -15.2% |
| FY2024 | 2024-12-31 | 101.96M | +39.1% |
| FY2023 | 2023-12-31 | 73.32M | +24.7% |
| FY2022 | 2022-12-31 | 58.77M | +40.7% |
| FY2021 | 2021-12-31 | 41.77M | — |
Selling, General & Admin vs competitors
How RCKT compares with its peers on the latest reported figures
- RCKT's LTM Mar 2026 selling, general & admin of $75.11M is the 2nd highest of the 10 companies compared; the peer median is $32.75M.
- Its year-over-year change of -30.1% is the lowest of 9, against a peer median of +10.6%.
- Over three fiscal years its annual growth of +13.7% compares with a peer median of +7.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $142.24M | +17.3% | +60.5% | 153.6% | |
| LTM Mar 2026 | $75.11M | -30.1% | +13.7% | — | |
| LTM Mar 2026 | $42.51M | -16.5% | +1.9% | 2295.5% | |
| LTM Mar 2026 | $40.91M | +18.8% | +10.3% | — | |
| LTM Mar 2026 | $38.19M | +65.9% | +17.2% | — | |
| LTM Mar 2026 | $32.75M | -0.8% | +0.8% | — | |
| LTM Mar 2026 | $23.71M | +3.3% | +7.6% | — | |
| LTM Mar 2026 | $20.62M | +11.6% | +2.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $18.21M | — | +110.6% | — |
| LTM Mar 2026 | $6.23M | +9.7% | -4.3% | — | |
| Peer median (excluding RCKT) | $32.75M | +10.6% | +7.6% | 1224.6% | |
Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.03M |
| Gross Profit | 0 | 0 | 0 | 0 | (11.03M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 125.48M | 165.57M | 186.34M | 171.24M | 142.02M |
| Selling, General & Admin | 41.77M | 58.77M | 73.32M | 101.96M | 86.5M |
| Operating Expenses | 167.25M | 224.34M | 259.66M | 273.21M | 217.49M |
| Depreciation & Amortization | 5.37M | 6.27M | 7.1M | 9.38M | 11.03M |
| EBITDA | (157.81M) | (213.69M) | (236.62M) | (247.49M) | (210.21M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (167.25M) | (224.34M) | (259.66M) | (273.21M) | (228.52M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 3.07M | 3.89M | 15.94M | 18.22M | 10.62M |
| Interest Expense | 5.89M | 1.91M | 1.88M | 1.89M | 1.89M |
| Other Income / Expenses | (1.82M) | 2.48M | 14.06M | 14.46M | 5.39M |
| Income Before Tax | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (169.07M) | (221.86M) | (245.6M) | (258.75M) | (223.12M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| EPS (Diluted) | (2.68) | (3.26) | (2.92) | (2.73) | (2.01) |
| Weighted Avg Shares | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
| Weighted Avg Shares (Diluted) | 63.24M | 68.15M | 84.01M | 94.81M | 111.12M |
Rocket Pharmaceuticals, Inc.
NASDAQ:RCKT
Intrinsic Alpha fair value
Locked
Current Price
$2.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.